{"id":"dep-ru","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"DEP-Ru works by activating dopamine receptors in the brain, which can help to improve symptoms of certain neurological disorders. However, the exact mechanism of action is not fully understood and requires further research.","oneSentence":"DEP-Ru is a small molecule that targets the dopamine receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:02.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT06951971","phase":"PHASE2, PHASE3","title":"Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-06-01","conditions":"Hemophagocytic Lymphohistiocytosis (HLH)","enrollment":30},{"nctId":"NCT03533790","phase":"PHASE3","title":"DEP-Ru Regimen as a Salvage Therapy for HLH","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2018-06","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DEP-Ru","genericName":"DEP-Ru","companyName":"Beijing Friendship Hospital","companyId":"beijing-friendship-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DEP-Ru is a small molecule that targets the dopamine receptor. Used for Parkinson's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}